Skip to main content

FDA Approval of Roche Cancer Drug Confirms Beginning of New Oncology Era | The Motley Fool

By September 16, 2019News
roche-logo

roche-logo

With nothing more than a passing glance, the U.S. Food & Drug Administration’s (FDA) approval of Roche Holdings’ (OTC:RHHBY) cancer drug entrectinib last month was a run-of-the-mill announcement. In fact, it was almost boilerplate in its tone and feel.

{iframe}https://www.fool.com/investing/2019/09/11/fda-approval-of-roche-cancer-drug-confirms-beginni.aspx{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.